Compare Enveric Biosciences Inc (ENVB) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Charles Schwab Corporation Common Stock trades at $107.04 (market cap $186.75B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 30121× Enveric Biosciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SCHW | |
|---|---|---|
Market Cap | $6.20M | $186.75B |
Sector | Health | Financials |
52-Week High | $17.40 | $108.02 |
52-Week Low | $1.27 | $85.35 |
Enterprise Value | $1.30M | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Charles Schwab (SCHW) trades at $107.60, down 0.06% on the day, near its all-time high of $109.05. The stock shows strong bullish momentum with earnings beats in recent quarters and a consensus analyst price target of $122.33. Revenue grew to $23.92 billion in 2025, with net income margin improving to 38.79%. Technical indicators signal bullish trends, though RSI levels suggest overbought conditions.
Outlook remains positive with robust earnings growth and institutional support, but risks include litigation exposure and competitive pressures. The stock offers upside potential aligned with analyst targets, contingent on sustained operational performance and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
